20/20 BioLabs secured an exclusive U.S. license to integrate ROKIT Healthcare's chronic kidney disease (CKD) prediction algorithm into its OneTest for Longevity platform. The agreement strengthens 20/20 BioLabs' analytics capabilities in the growing longevity/healthtech market and could modestly expand its product offering and addressable market, though near-term revenue impact is unclear without commercialization or pricing details.
20/20 BioLabs secured an exclusive U.S. license to integrate ROKIT Healthcare's chronic kidney disease (CKD) prediction algorithm into its OneTest for Longevity platform. The agreement strengthens 20/20 BioLabs' analytics capabilities in the growing longevity/healthtech market and could modestly expand its product offering and addressable market, though near-term revenue impact is unclear without commercialization or pricing details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
